Biogen Pharmachem Industries Inc Stock Price Today (NSE: BIOGEN)
Fundamental Score
Biogen Pharmachem Industries Inc Share Price Live NSE/BSE & Institutional Fundamental Analysis
Biogen Pharmachem Industries Inc share price today is ₹0.69, up +0.00% on NSE/BSE as of 17 February 2026. Biogen Pharmachem Industries Inc (BIOGEN) is a Small-cap company in the Other Financial Services sector with a market capitalisation of ₹68.60 (Cr). The 52-week high for BIOGEN share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 39.88x, BIOGEN is currently trading above its industry average P/E of 30.94x. The company has a Return on Equity (ROE) of -0.39% and a debt-to-equity ratio of 0.00.
Biogen Pharmachem Industries Inc Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Biogen Pharmachem Industries Inc Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Biogen Pharmachem Inc Share Price: A Financial Analysis
The Other Financial Services sector is currently experiencing increased volatility driven by evolving regulatory landscapes and shifting investor sentiment towards specialized lending models. This analysis focuses on Biogen Pharmachem Inc share price, which currently stands at ₹0.6899999976158142. Understanding its valuation metrics, particularly its Price-to-Earnings (PE) ratio of 39.88 and Return on Capital Employed (ROCE) of -0.39%, is crucial for assessing its financial health within this dynamic environment. This assessment forms part of an extensive, 80-parameter fundamental audit verified by Sweta Mishra.
A PE ratio of 39.88 suggests that investors are willing to pay a relatively high price for each rupee of earnings. This could indicate expectations of future growth, but should be viewed cautiously in light of the company’s negative ROCE. The negative ROCE of -0.39% is a significant concern. It signifies that Biogen Pharmachem Inc. is not generating profits from its invested capital, which weakens its competitive advantage or moat. A strong ROCE is often indicative of efficiency and a solid economic moat, allowing a company to outperform its competitors.
Comparing Biogen Pharmachem Inc. to its peers reveals further insights. Consider
Sumedha Fiscal Services Ltd. While we cannot comment directly on management quality without deeper investigation, consistent profitability and higher ROCE in peer companies (if observed) might suggest different operational efficiencies and strategic decision-making processes. Further investigation into Biogen Pharmachem Inc.’s cost structure and revenue generation would be beneficial to determine the root causes of the negative ROCE and high PE ratio.In conclusion, the Biogen Pharmachem Inc share price should be viewed in the context of its high PE ratio and negative ROCE. The financial data suggests caution. Further investigation is warranted to understand the drivers of these metrics and the company's long-term sustainability within the Other Financial Services sector. This analysis is observational and does not constitute financial advice.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Biogen Pharmachem Industries Inc Fundamental Analysis & Valuation Benchmarking
Educational evaluation of BIOGEN across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Robust Profit Growth (51.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
5 factors identified
Below-Average Return on Equity (-0.39%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (-0.39%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Margin Pressure Concerns (0.26%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Low Promoter Commitment (0.00%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Biogen Pharmachem Industries Inc Financial Statements
Comprehensive financial data for Biogen Pharmachem Industries Inc including income statement, balance sheet and cash flow
About BIOGEN (Biogen Pharmachem Industries Inc)
Biogen Pharmachem Industries Inc (BIOGEN) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Other Financial Services sector with a current market capitalisation of ₹68.60 (Cr). Biogen Pharmachem Industries Inc has delivered a Return on Equity (ROE) of -0.39% and a ROCE of -0.39%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking BIOGEN share price can monitor key metrics including P/E ratio, promoter holding of 0.00%, and quarterly earnings growth.
Company Details
Key Leadership
Latest News
BIOGEN Share Price: Frequently Asked Questions
What is the current share price of Biogen Pharmachem Industries Inc (BIOGEN)?
As of 17 Feb 2026, 10:08 am IST, Biogen Pharmachem Industries Inc share price is ₹0.69. The BIOGEN stock has a market capitalisation of ₹68.60 (Cr) on NSE/BSE.
Is BIOGEN share price Overvalued or Undervalued?
BIOGEN share price is currently trading at a P/E ratio of 39.88x, compared to the industry average of 30.94x. Based on this relative valuation, the Biogen Pharmachem Industries Inc stock appears to be Overvalued against its sector peers.
What is the 52-week high and low of BIOGEN share price?
The 52-week high of BIOGEN share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Biogen Pharmachem Industries Inc share price?
Key factors influencing BIOGEN share price include quarterly earnings growth (Sales Growth: N/A%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Biogen Pharmachem Industries Inc a good stock for long-term investment?
Biogen Pharmachem Industries Inc shows a 5-year Profit Growth of N/A% and an ROE of -0.39%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in BIOGEN shares.
How does Biogen Pharmachem Industries Inc compare with its industry peers?
Biogen Pharmachem Industries Inc competes with major peers in the Other Financial Services. Investors should compare BIOGEN share price P/E of 39.88x and ROE of -0.39% against the industry averages to determine competitive standing.
What is the P/E ratio of BIOGEN and what does it mean?
BIOGEN share price has a P/E ratio of 39.88x compared to the industry average of 30.94x. Investors pay ₹40 for every ₹1 of annual earnings.
How is BIOGEN performing according to Bull Run's analysis?
BIOGEN has a Bull Run fundamental score of 13.5/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does BIOGEN belong to?
BIOGEN operates in the Other Financial Services industry. This classification helps understand the competitive landscape and sector-specific trends affecting Biogen Pharmachem Industries Inc share price.
What is Return on Equity (ROE) and why is it important for BIOGEN?
BIOGEN has an ROE of -0.39%, which suggests challenges in generating returns from shareholders equity. ROE measures how efficiently Biogen Pharmachem Industries Inc generates profits from shareholders capital.
How is BIOGEN debt-to-equity ratio and what does it indicate?
BIOGEN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is BIOGEN dividend yield and is it a good dividend stock?
BIOGEN offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Biogen Pharmachem Industries Inc shares.
How has BIOGEN share price grown over the past 5 years?
BIOGEN has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in BIOGEN and why does it matter?
Promoters hold 0.00% of BIOGEN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Biogen Pharmachem Industries Inc.
What is BIOGEN market capitalisation category?
BIOGEN has a market capitalisation of ₹69 crores, placing it in the Small-cap category.
How volatile is BIOGEN stock?
BIOGEN has a beta of N/A. A beta > 1 suggests the Biogen Pharmachem Industries Inc stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is BIOGEN operating profit margin trend?
BIOGEN has a 5-year average Operating Profit Margin (OPM) of 0.26%, indicating the company's operational efficiency.
How is BIOGEN quarterly performance?
Recent quarterly performance shows Biogen Pharmachem Industries Inc YoY Sales Growth of N/A% and YoY Profit Growth of 51.00%.
What is the institutional holding pattern in BIOGEN?
BIOGEN has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Biogen Pharmachem Industries Inc stock.